In our study, we used a two-sample MR approach to assess the causal impact of TBIL and DBIL on hematological malignancies, including AML, CML, CLL, FL, HL, NKTL, and MM. The gene discussed is SCYL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.